What Is GCAR1 and How Does This First-in-Class CAR-T Therapy Target Solid Tumors?

GPNMB is highly expressed in several solid tumors, including:

• Alveolar soft part sarcoma (ASPS)
• Other MiT/TFE fusion-driven cancers
• Subsets of renal cell carcinoma (RCC)
• Triple-negative breast cancer (TNBC)
• Undifferentiated pleomorphic sarcoma (UPS)
• Glioblastoma (GBM)

This expression pattern makes GPNMB a clinically tested, safety-proven immunotherapy target .

Early Clinical Results in Alveolar Soft Part Sarcoma (ASPS)

The first-in-human trial for GCAR1 was completed in 2023 . To date, two patients have been treated in the clinical trial at the Arthur J.E. Child Comprehensive Cancer Centre in Calgary . The results, while very preliminary, have been notable:

• One patient's life was extended by 18 months before they ultimately passed away from their cancer .
• The second patient experienced significant tumor shrinkage and continues to respond to treatment .
• Researchers report that GCAR1 is the first therapy of its kind to show strong promise in treating ASPS .

Important caveat: These results come from a very small number of patients (n=2) and were reported in news coverage rather than a peer-reviewed publication. The rigorous Phase I data have not yet been published in a medical journal.

Additional Cancers Being Tested in the Ongoing Phase I/II Trial

The current Phase I study (NCT07297667, starting March 2026) is enrolling patients with relapsed/refractory GPNMB-expressing solid tumors, specifically :

• Alveolar soft part sarcoma (ASPS) – the lead indication
• Renal cell carcinoma (excluding clear cell subtype)
• Triple-negative breast cancer (TNBC)

A separate dedicated trial for relapsed ASPS (NCT06813417) is also active .

Why Solid Tumors Are a Persistent Challenge for CAR-T Therapy

CAR-T therapy has been highly successful in blood cancers, but solid tumors pose several major obstacles :

• Immunosuppressive tumor microenvironment (TME): Solid tumors create a hostile environment that actively dampens CAR-T cell function through regulatory T cells, myeloid-derived suppressor cells, and inhibitory cytokines . Academic reviews confirm that the TME is one of the greatest challenges affecting CAR-T cell efficacy because it hampers trafficking, affects metabolic function, and creates an immunosuppressive environment leading to T-cell exhaustion .
• Poor trafficking and infiltration: CAR-T cells struggle to migrate into and penetrate dense solid tumor tissue . The tumor stroma, composed of desmoplastic tissue and aberrant vasculature, creates a physical barrier that severely limits access .
• Antigen heterogeneity and loss: Solid tumors often have mixed antigen expression, allowing antigen-negative cancer cells to escape and cause relapse . Even when an antigen is initially present, tumor cells can downregulate or lose it entirely under selective pressure from therapy .
• Lack of truly tumor-specific antigens: Many targets are also expressed on normal tissues, raising the risk of on-target, off-tumor toxicity . Unlike the nearly perfect tumor specificity of CD19 in B-cell malignancies, most solid tumor antigens are tumor-associated antigens (TAAs) that appear on healthy tissues at lower levels .
• Physical barriers: Desmoplastic stroma, abnormal vascularization, hypoxia, and altered nutrient availability all impede CAR-T cell access and persistence . Academic sources describe a dense extracellular matrix and cancer-associated fibroblasts that create a rigid stromal network blocking access to the tumor core .

GCAR1's targeting of GPNMB aims to address the antigen-specificity challenge by focusing on a protein that is highly expressed across multiple solid tumor types but has a well-characterized safety profile. Its early results suggest it is managing some of these hurdles in at least a subset of patients, but larger, peer-reviewed studies are needed to confirm the finding.